D.E. Shaw & Co’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.02M | Sell |
4,814
-142,913
| -97% | -$28M | ﹤0.01% | 3734 |
|
|
2026
Q1 | $29M | Sell |
147,727
-181,007
| -55% | -$35.2M | 0.02% | 925 |
|
|
2025
Q4 | $57M | Buy |
+328,734
| New | +$59.9M | 0.03% | 648 |
|
|
2025
Q1 | – | Sell |
-79,369
| Closed | -$12M | – | 4360 |
|
|
2024
Q4 | $12M | Buy |
79,369
+76,397
| +2,571% | +$11.9M | 0.01% | 1382 |
|
|
2024
Q3 | $461K | Sell |
2,972
-11,197
| -79% | -$1.67M | ﹤0.01% | 3746 |
|
|
2024
Q2 | $1.94M | Sell |
14,169
-94,502
| -87% | -$12.9M | ﹤0.01% | 2683 |
|
|
2024
Q1 | $14.5M | Buy |
108,671
+47,849
| +79% | +$6.21M | 0.01% | 1124 |
|
|
2023
Q4 | $8.39M | Buy |
60,822
+38,347
| +171% | +$5.04M | 0.01% | 1497 |
|
|
2023
Q3 | $2.74M | Sell |
22,475
-48,344
| -68% | -$6.44M | ﹤0.01% | 2324 |
|
|
2023
Q2 | $9.95M | Sell |
70,819
-38,641
| -35% | -$5.33M | 0.01% | 1341 |
|
|
2023
Q1 | $15.5M | Buy |
109,460
+46,530
| +74% | +$6.66M | 0.02% | 1055 |
|
|
2022
Q4 | $9.84M | Buy |
62,930
+21,562
| +52% | +$3.1M | 0.01% | 1444 |
|
|
2022
Q3 | $5.08M | Sell |
41,368
-10,514
| -20% | -$1.38M | 0.01% | 2072 |
|
|
2022
Q2 | $6.9M | Sell |
51,882
-15,318
| -23% | -$2.09M | 0.01% | 1763 |
|
|
2022
Q1 | $9.2M | Sell |
67,200
-316,975
| -83% | -$44.2M | 0.01% | 1668 |
|
|
2021
Q4 | $66.5M | Buy |
384,175
+197,774
| +106% | +$30.1M | 0.06% | 427 |
|
|
2021
Q3 | $27.1M | Sell |
186,401
-84,377
| -31% | -$12.3M | 0.02% | 840 |
|
|
2021
Q2 | $35.7M | Sell |
270,778
-11,041
| -4% | -$1.45M | 0.03% | 710 |
|
|
2021
Q1 | $36.2M | Buy |
281,819
+184,722
| +190% | +$22.8M | 0.03% | 636 |
|
|
2020
Q4 | $11.6M | Buy |
+97,097
| New | +$11.8M | 0.01% | 1298 |
|
|
2020
Q2 | – | Sell |
-13,862
| Closed | -$1.47M | – | 4034 |
|
|
2020
Q1 | $1.11M | Sell |
13,862
-129,936
| -90% | -$13.5M | ﹤0.01% | 2653 |
|
|
2019
Q4 | $15.4M | Buy |
143,798
+138,604
| +2,669% | +$14.5M | 0.02% | 965 |
|
|
2019
Q3 | $556K | Sell |
5,194
-598
| -10% | -$61.4K | ﹤0.01% | 3164 |
|
|
2019
Q2 | $590K | Sell |
5,792
-84,720
| -94% | -$8.14M | ﹤0.01% | 2992 |
|
|
2019
Q1 | $8.14M | Sell |
90,512
-272,007
| -75% | -$23.6M | 0.01% | 1242 |
|
|
2018
Q4 | $30.2M | Buy |
362,519
+154,086
| +74% | +$14.4M | 0.04% | 515 |
|
|
2018
Q3 | $22.5M | Sell |
208,433
-40,642
| -16% | -$4.46M | 0.03% | 721 |
|
|
2018
Q2 | $27.4M | Buy |
249,075
+62,266
| +33% | +$6.49M | 0.04% | 575 |
|
|
2018
Q1 | $18.7M | Sell |
186,809
-218,560
| -54% | -$22.4M | 0.03% | 694 |
|
|
2017
Q4 | $39.9M | Buy |
405,369
+391,122
| +2,745% | +$37.1M | 0.06% | 417 |
|
|
2017
Q3 | $1.33M | Buy |
14,247
+4,490
| +46% | +$477K | ﹤0.01% | 2302 |
|
|
2017
Q2 | $1.08M | Buy |
9,757
+6,357
| +187% | +$672K | ﹤0.01% | 2364 |
|
|
2017
Q1 | $334K | Sell |
3,400
-1,503
| -31% | -$143K | ﹤0.01% | 2921 |
|
|
2016
Q4 | $451K | Sell |
4,903
-79,051
| -94% | -$6.81M | ﹤0.01% | 2906 |
|
|
2016
Q3 | $7.11M | Sell |
83,954
-36,803
| -30% | -$3.09M | 0.01% | 1082 |
|
|
2016
Q2 | $9.83M | Sell |
120,757
-162,128
| -57% | -$12.3M | 0.02% | 904 |
|
|
2016
Q1 | $20.2M | Buy |
282,885
+149,134
| +112% | +$10M | 0.04% | 542 |
|
|
2015
Q4 | $9.52M | Buy |
133,751
+45,327
| +51% | +$3.05M | 0.01% | 995 |
|
|
2015
Q3 | $5.43M | Sell |
88,424
-220,942
| -71% | -$15.4M | 0.01% | 1335 |
|
|
2015
Q2 | $22.4M | Buy |
309,366
+150,912
| +95% | +$11.1M | 0.03% | 596 |
|
|
2015
Q1 | $12.2M | Buy |
158,454
+144,672
| +1,050% | +$10.4M | 0.02% | 854 |
|
|
2014
Q4 | $924K | Buy |
+13,782
| New | +$870K | ﹤0.01% | 2892 |
|
|
2014
Q2 | – | Sell |
-96,800
| Closed | -$5.61M | – | 4254 |
|
|
2014
Q1 | $5.61M | Sell |
96,800
-65,302
| -40% | -$3.5M | 0.01% | 1495 |
|
|
2013
Q4 | $8.68M | Buy |
+162,102
| New | +$9.61M | 0.01% | 1250 |
|
Other funds holding DGX
EIG
D.E. Shaw & Co's DGX Position: Q2 2026 in Review
D.E. Shaw & Co reduced its Quest Diagnostics (DGX) stake by 97% in Q2 2026, selling an estimated $28M and leaving 4,814 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #3734.
D.E. Shaw & Co first reported a position in DGX in Q4 2013 and has held it in 44 quarters since. The position peaked at $66.5M in Q4 2021. 1,099 funds tracked by Wall St. Rank hold DGX as of Q2 2026.
- D.E. Shaw & Co held 4,814 shares of Quest Diagnostics worth $1.02M as of Q2 2026.
- D.E. Shaw & Co sold 142,913 Quest Diagnostics shares in Q2 2026, an estimated $28M.
- Quest Diagnostics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #3734 holding.
- D.E. Shaw & Co first reported a position in Quest Diagnostics in Q4 2013 and has held it in 44 quarters since.
- D.E. Shaw & Co's Quest Diagnostics position peaked at $66.5M in Q4 2021.
- 1,099 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.
Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.